Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HAWK Biosystems, formerly Fastbase Solutions, is a Spain-based biotechnology and diagnostics company developing spatial functional proteomics tools for research and clinical applications. Its core platform, QF-Pro®, is an antibody-based FRET-FLIM technology that quantifies protein function, protein-protein interactions, and post-translational states directly in tissue samples with high spatial resolution. The company is focused particularly on immuno-oncology and companion-diagnostics-style applications, including assays for PD-1/PD-L1 checkpoint engagement in non-small cell lung cancer. In addition to the QF-Pro® assay chemistry, HAWK offers related software, reagent kits, and the Violet 3.0 benchtop imaging system. The business appears to operate as a platform and biomarker-enablement company rather than a traditional therapeutics developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HAWK Biosystems.